DBCO-PEG3-Glu-Val-Cit-PABC-MMAE

DBCO-PEG3-Glu-Val-Cit-PABC-MMAE

• CAS Number: 2861998-23-2
• UNSPSC Description: DBCO-PEG3-Glu-Val-Cit-PABC-MMAE is a drug-linker conjugate for ADC. DBCO-PEG3-Glu-Val-Cit-PABC-MMAE contains a potent tubulin inhibitor Monomethyl auristatin E (MMAE, HY-15162) and can be used for synthesis of dual-drug ADC[1].
• Target Antigen: Drug-Linker Conjugates for ADC
• Type: ADC Related
• Related Pathways: Antibody-drug Conjugate/ADC Related
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/dbco-peg3-glu-val-cit-pabc-mmae.html
• Smiles: O=C(N1[C@](CCC1)([H])[C@H](OC)[C@@H](C)C(N[C@H](C)[C@H](C2=CC=CC=C2)O)=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(OCC(C=C3)=CC=C3NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC([C@H](CCC(O)=O)NC(COCCOCCOCCNC(CCC(N4C5=CC=CC=C5C#CC6=CC=CC=C6C4)=O)=O)=O)=O)=O)=O)=O)=O)=O
• Molecular Weight: 1729.06
• References & Citations: [1]Yamazaki CM, et al. Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat Commun. 2021 Jun 10;12(1):3528.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported